Successful treatment of diffuse large b-cell lympoma following waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab

Keita Uchino, Hidekazu Sameshima, Toshihiro Miyamoto, Tadafumi Iino, Koji Kato, Hideho Henzan, Ken Ichi Aoki, Koji Nagafuji, Hisashi Gondo, Mine Harada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report a 72-year-old man with Waldenström's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalInternal Medicine
Volume43
Issue number2
DOIs
Publication statusPublished - Feb 1 2004

Fingerprint

Waldenstrom Macroglobulinemia
Combination Drug Therapy
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Monoclonal Antibodies
Rituximab

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Successful treatment of diffuse large b-cell lympoma following waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. / Uchino, Keita; Sameshima, Hidekazu; Miyamoto, Toshihiro; Iino, Tadafumi; Kato, Koji; Henzan, Hideho; Aoki, Ken Ichi; Nagafuji, Koji; Gondo, Hisashi; Harada, Mine.

In: Internal Medicine, Vol. 43, No. 2, 01.02.2004, p. 131-134.

Research output: Contribution to journalArticle

Uchino, Keita ; Sameshima, Hidekazu ; Miyamoto, Toshihiro ; Iino, Tadafumi ; Kato, Koji ; Henzan, Hideho ; Aoki, Ken Ichi ; Nagafuji, Koji ; Gondo, Hisashi ; Harada, Mine. / Successful treatment of diffuse large b-cell lympoma following waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. In: Internal Medicine. 2004 ; Vol. 43, No. 2. pp. 131-134.
@article{e9dc7bbe353c4890bb4cc13d47d3fa7d,
title = "Successful treatment of diffuse large b-cell lympoma following waldenstr{\"o}m's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab",
abstract = "We report a 72-year-old man with Waldenstr{\"o}m's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.",
author = "Keita Uchino and Hidekazu Sameshima and Toshihiro Miyamoto and Tadafumi Iino and Koji Kato and Hideho Henzan and Aoki, {Ken Ichi} and Koji Nagafuji and Hisashi Gondo and Mine Harada",
year = "2004",
month = "2",
day = "1",
doi = "10.2169/internalmedicine.43.131",
language = "English",
volume = "43",
pages = "131--134",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Successful treatment of diffuse large b-cell lympoma following waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab

AU - Uchino, Keita

AU - Sameshima, Hidekazu

AU - Miyamoto, Toshihiro

AU - Iino, Tadafumi

AU - Kato, Koji

AU - Henzan, Hideho

AU - Aoki, Ken Ichi

AU - Nagafuji, Koji

AU - Gondo, Hisashi

AU - Harada, Mine

PY - 2004/2/1

Y1 - 2004/2/1

N2 - We report a 72-year-old man with Waldenström's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.

AB - We report a 72-year-old man with Waldenström's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.

UR - http://www.scopus.com/inward/record.url?scp=12144290294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144290294&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.43.131

DO - 10.2169/internalmedicine.43.131

M3 - Article

C2 - 15005256

AN - SCOPUS:12144290294

VL - 43

SP - 131

EP - 134

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 2

ER -